To address this concern, our study provided a novel 5-biomarker signature consisting of MMP-3, MMP-7, MMP-9, MMP-10, and TIMP-1 that effectively characterized RA-ILD+versus IPF. This evidence concerns the gene TIMP1 and interstitial lung disease.